Date: 2015-12-22
Type of information: Construction of new premises
Compound: biopharmaceutical production facility in Vienna (Austria)
Company: Boehringer Ingelheim (Germany)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details:
- • On December 22, 2015, Boehringer Ingelheim announced that the company will make a significant investment in biopharmaceutical production at its Vienna (Austria) site. There the research-driven pharmaceutical company will establish a new large-scale biopharmaceutical production facility for active ingredients manufactured using cell cultures. With the roughly half billion euro investment Boehringer Ingelheim will also create more than 400 new jobs in the Austrian capital. The exact investment and job numbers will be established as details are ironed out.
- In Vienna, Boehringer Ingelheim has up to now produced pharmaceutical active ingredients using microorganisms; over the next few years, cell culture technology will also be transferred there. At the Biberach site, two large-scale facilities for the market launch and cell culture based manufacture of biopharmaceuticals have already been operating successfully for many years. Biberach will remain Boehringer Ingelheim’s largest European cell culture and global launch site for biopharmaceutical products. The new production plant will go into operation by 2021.
Financial terms:
Latest news:
Is general: Yes
